TALWIN COMPOUND Drug Patent Profile

Which patents cover Talwin Compound, and what generic alternatives are available?

Talwin Compound is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in TALWIN COMPOUND is aspirin; pentazocine hydrochloride. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; pentazocine hydrochloride profile page.

Summary for TALWIN COMPOUND

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	TALWIN COMPOUND at DailyMed

US Patents and Regulatory Information for TALWIN COMPOUND

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	TALWIN COMPOUND	aspirin; pentazocine hydrochloride	TABLET;ORAL	016891-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for TALWIN COMPOUND

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	TALWIN COMPOUND	aspirin; pentazocine hydrochloride	TABLET;ORAL	016891-001	Approved Prior to Jan 1, 1982	4,105,659

International Patents for TALWIN COMPOUND

See the table below for patents covering TALWIN COMPOUND around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	246157
Netherlands	6705466
Denmark	103236
United Kingdom	1000506
Brazil	6134479
Netherlands	6705465
Germany	1445153	1,2,3,4,5,6-HEXAHYDRO-3-(3-METHYL-2BUTENYL)-6,11-DIMETHYL-8-HYDROXY-2,6METHANO-3-BENZAZOCIN, SEINE SAEUREADDITIONSSALZE UND VERFAHREN ZU IHRER HERSTELLUNG

TALWIN COMPOUND Market Analysis and Financial Projection

Last updated: February 13, 2026

Market Dynamics for Talwin Compound

Talwin compound, containing pentazocine, is an opioid analgesic initially introduced in the 1960s. Its primary use is for moderate to severe pain management. Despite its long presence, the drug faces significant market constraints related to regulatory issues, safety profile concerns, and competition from newer analgesics.

Regulatory Environment

The Drug Enforcement Administration (DEA) classifies pentazocine as a Schedule IV controlled substance, limiting prescribing restrictions but raising awareness of dependency risks. Since the early 2000s, tighter policies on opioid prescriptions have reduced overall opioid dispensation, impacting drugs like Talwin.

Market Size and Usage

Global sales for pentazocine products, including Talwin, are estimated in the low hundreds of millions USD annually, according to IQVIA data. Usage is concentrated in the United States, where opioids account for a significant portion of pain management, but Talwin's market share has declined relative to other opioids like oxycodone and morphine.

Competitive Landscape

The analgesic market shifted toward combination drugs and opioids with better safety profiles. Drugs like tramadol and buprenorphine have gained prominence due to lower dependency potential. Talwin’s reputation is impacted by safety concerns, especially its psychiatric and dependence risks, limiting its market growth.

Patent and Formulation Status

The original Talwin patent has expired, leading to generic versions. Current formulations are limited, with few new patent-protected variants in development. The fixed high barriers to reformulation, due to regulatory restrictions, hinder innovation.

Financial Trajectory of Talwin Compound

Historical Financial Performance

Historically, Talwin accounted for over $200 million annually in global sales during peak years in the 1980s. Since then, sales have declined steadily, driven by safety issues, regulatory restrictions, and competitive pressures.

Current Sales Data

Accessing recent market reports indicates that sales are now below $50 million globally. The drug’s market share has fallen substantially, primarily replaced by newer opioids with improved safety profiles.

R&D Investment and Pipeline

No significant recent R&D investments have been reported to improve Talwin. The drug is considered a mature product with limited future growth prospects, absent reformulation or new delivery systems.

Market Outlook and Growth Potential

Future prospects for Talwin are limited. The general movement towards abuse-deterrent formulations and restrictive opioid prescribing policies decreases the likelihood of a significant resurgence. The trend favors drugs with lower dependency risks or non-opioid alternatives.

Summary of Key Market and Financial Trends

Aspect	Data/Observation
Peak annual sales	~$200 million (1980s)
Current sales estimate	<$50 million globally
Market share decline	Over 75% since early 2000s
Regulatory impact	Scheduling and prescription controls limit growth
Competitive environment	Shift toward safer alternative analgesics
R&D activity	Minimal; no promising reformulation in pipeline

Key Takeaways

• Talwin’s market presence diminishes due to safety concerns, regulatory restrictions, and competition.
• Sales have declined sharply since the 1980s, with current global revenue below $50 million.
• Limited innovation or reformulation efforts restrict future growth potential.
• Regulatory or legal developments could further constrain the drug’s market.
• The market trend favors non-opioid analgesics or opioids with lower dependency risks.

FAQs

1. What factors contributed to the decline in Talwin’s market share?
Safety concerns, regulatory restrictions, and the advent of safer analgesics prompted a decline in Talwin's market share.

2. Are there any new formulations of Talwin in development?
No significant reformulations or new delivery systems are currently reported; the drug remains a mature product.

3. How does Talwin compare with other opioids in terms of dependency risk?
Pentazocine presents dependency risks similar to other opioids but is considered less addictive than drugs like oxycodone; however, safety concerns limit its appeal.

4. What is the future outlook for Talwin’s sales?
Sales are expected to remain low and decline further due to market shifts toward safer pain management options and regulatory constraints.

5. Could regulatory changes revive Talwin’s market?
Unlikely, unless new formulations with significantly reduced abuse potential are developed and receive approval.

---

Citations
[1] IQVIA, "Global Prescription Drug Sales," 2022.
[2] U.S. DEA Schedule IV listing for pentazocine.
[3] Medical and pharmaceutical literature on opioid analgesics and safety profiles.